ReviewInfluenza and other respiratory viruses2021
Influenza and COVID-19: What does co-existence mean?
Review in Influenza and other respiratory viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The global trends and clinical progress in influenza co-infection: a visualization and bibliometric analysis (2005-2025).Frontiers in microbiology · 2025Pooled it
- Vaccination against influenza viruses reduces infection, not hospitalization or death, from respiratory COVID-19: A systematic review and meta-analysis.Journal of medical virology · 2024Pooled it
- Pooled it
- Immunogenicity and safety of concomitant administration of recombinant COVID-19 vaccine and quadrivalent inactivated influenza vaccine in Chinese adults: An open-label, randomized, controlled trial.Human vaccines & immunotherapeutics · 2024Trial
- Surface proteome of plasma extracellular vesicles differentiates between SARS-CoV-2 and influenza infection.Virulence · 2026Article
- An adaptive method of emergency department syndromic surveillance to nowcast the frequency of presentations that will have a severe 28-day outcome following influenza or COVID-19 infection: a retrospective analytical record linkage study.American journal of epidemiology · 2026Article
- Comparative clinical and epidemiological characteristics of influenza and COVID-19 in hospitalized pediatric patients in Romania during and after the SARS-CoV-2 pandemic.Journal of medicine and life · 2026Observational
- Effects of a smartphone-based chatbot intervention on influenza and COVID-19 vaccine uptake among South Asians.NPJ digital medicine · 2025Article
- Estimated incidence of influenza in Guangzhou, China, 2019-2022.Infectious medicine · 2025Article
- Changes in Antiviral Prescribing for Children With Influenza in US Emergency Departments.JAMA network open · 2025Article
- Epidemiological characteristics of influenza after COVID-19 pandemic in Zhejiang province, China.BMC infectious diseases · 2025Article
- The Concurrent Identification of SARS-Cov-2 and Influenza A/B Viruses in Nasopharyngeal Swabs Using Multiplex Real-time PCR.Archives of Razi Institute · 2025Article
- Evaluation of the cobas SARS-CoV-2 & Influenza A/B v2 assay for detecting SARS-CoV-2 and influenza A and B viruses in nasopharyngeal swab specimens.Microbiology spectrum · 2025Article
- A Bayesian spatial-temporal varying coefficients model for estimating excess deaths associated with respiratory infections.Journal of the Royal Statistical Society. Series A, (Statistics in Society) · 2025Article
- Influenza Vaccination Coverage and Determinants of New Vaccinations During the COVID-19 Pandemic in Spain (ENE-COVID): Nationwide Population-Based Study.JMIR public health and surveillance · 2025Article
- Respiratory virus infection dynamics and genomic surveillance to detect seasonal influenza subtypes in wastewater: A longitudinal study in Bengaluru, India.PLOS global public health · 2025Article
- An evaluation of barriers and facilitators to implementing multiplex rapid antigen testing for SARS-CoV-2 and influenza A and B in congregate living settings.Frontiers in public health · 2025Article
- Influenza A (H1N1) and COVID-19 Pneumonias: An Evaluation in the Light of New Hematologic Indices.Journal of inflammation research · 2025Article
- Article
- Chemical composition combined with network pharmacology and quality markers analysis for the quality evaluation of Qing-fei-da-yuan granules.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 continues to have a major impact on healthcare and social systems throughout the world. As the clinical and epidemiological features of COVID-19 have many parallels with influenza, it is important to ensure optimal management of both respiratory diseases as we anticipate their continued co-circulation. In particular, there is a need to ensure that effective surveillance and diagnostic capacities are in place to monitor these and other respiratory viruses, as this will underpin decisions on the appropriate clinical management of the respective diseases. As such, we propose a series of key recommendations for stakeholders, public health authorities, primary care physicians and surveillance bodies that will help mitigate the combined risks of concurrent influenza epidemics and the COVID-19 pandemic. We advocate the judicious use of influenza vaccines and antivirals, particularly among groups at high risk of complications, with healthcare workers also considered a priority for vaccination. It is likely that the increased use of emerging technologies such as telemedicine and contact tracing will permanently change our approach to managing infectious disease. The use of these technologies, alongside existing pharmaceutical strategies, will ensure that we achieve a holistic approach to the global public health measures needed to deal with the combined threat of influenza and COVID-19. Ensuring that this approach is optimal will be key as we move from a reactive pandemic response towards preparing for the long-term management of the remarkable clinical burden associated with these respiratory pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.